Medline Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 27, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	27,429	25,507	23,231	21,448
Revenue Growth (YoY)	18.07%	9.80%	8.31%	-
Cost of Revenue	19,974	18,531	17,346	16,231
Gross Profit	7,455	6,976	5,885	5,217
Selling, General & Admin	4,466	4,108	3,867	3,676
Amortization of Goodwill & Intangibles	705	685	662	660
Other Operating Expenses	34	15	20	20
Operating Expenses	5,205	4,808	4,549	4,356
Operating Income	2,250	2,168	1,336	861
Interest Expense	-1,017	-1,144	-1,213	-899
Interest & Investment Income	162	280	237	27
Currency Exchange Gain (Loss)	-66	4	-10	11
Other Non Operating Income (Expenses)	-4	-8	-	10
EBT Excluding Unusual Items	1,325	1,300	350	10
Merger & Restructuring Charges	-20	-20	-	-
Legal Settlements	49	-2	-166	-
Other Unusual Items	-7	-32	75	-
Pretax Income	1,347	1,246	264	10
Income Tax Expense	81	46	30	35
Net Income	1,266	1,200	234	-25
Net Income to Common	1,266	1,200	234	-25
Net Income Growth	441.03%	412.82%	-	-
Shares Outstanding (Basic)	17,480	17,467	17,500	-
Shares Outstanding (Diluted)	17,480	17,467	17,500	-
Shares Change (YoY)	-0.11%	-0.19%	-	-
EPS (Basic)	0.07	0.07	0.01	-
EPS (Diluted)	0.07	0.07	0.01	-
EPS Growth	441.66%	413.80%	-	-
Free Cash Flow	1,009	1,405	1,400	-67
Free Cash Flow Per Share	0.06	0.08	0.08	-
Gross Margin	27.18%	27.35%	25.33%	24.32%
Operating Margin	8.20%	8.50%	5.75%	4.01%
Profit Margin	4.62%	4.71%	1.01%	-0.12%
Free Cash Flow Margin	3.68%	5.51%	6.03%	-0.31%
EBITDA	3,253	3,145	2,287	1,794
EBITDA Margin	11.86%	12.33%	9.84%	8.36%
D&A For EBITDA	1,003	977	951	933
EBIT	2,250	2,168	1,336	861
EBIT Margin	8.20%	8.50%	5.75%	4.01%
Effective Tax Rate	6.01%	3.69%	11.36%	350.00%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q